In today’s recent session, 2.81 million shares of the Calidi Biotherapeutics Inc (AMEX:CLDI) have been traded, and its beta is 0.60. Most recently the company’s share price was $1.15, and it changed around $0.06 or 5.58% from the last close, which brings the market valuation of the company to $9.30M. CLDI at last check was trading at a discount to its 52-week high of $29.10, offering almost -2430.43% off that amount. The share price’s 52-week low was $0.73, which indicates that the recent value has risen by an impressive 36.52% since then. We note from Calidi Biotherapeutics Inc’s average daily trading volume that its 10-day average is 0.85 million shares, with the 3-month average coming to 252.11K.
Calidi Biotherapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CLDI as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Calidi Biotherapeutics Inc is expected to report earnings per share of -0.85 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
Instantly CLDI has been showing a green trend so far today with a performance of 5.58% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.2500 on recent trading dayincreased the stock’s daily price by 8.0%. The company’s shares are currently down -92.38% year-to-date, but still up 1.84% over the last five days. On the other hand, Calidi Biotherapeutics Inc (AMEX:CLDI) is -4.89% down in the 30-day period. We can see from the shorts that 0.11 million shares have been sold at a short interest cover period of 1.88 day(s).
The consensus price target as assigned by Wall Street analysts is $5.5, which translates to bulls needing to increase their stock price by 79.09% from its current value. Analyst projections state that CLDI is forecast to be at a low of $2 and a high of $9.
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Calidi Biotherapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -44.67 percent over the past six months and at a 74.68% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 39.30% in revenue this quarter, and will report an increase of 92.10% in the next quarter.
CLDI Dividends
Calidi Biotherapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Aug-13.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 22.78% of Calidi Biotherapeutics Inc shares, and 3.08% of them are in the hands of institutional investors. The stock currently has a share float of 3.99%.
Fidelity Extended Market Index Fund and Brinker Capital Destinations Tr-Destinations Multi Strategy Alt Fd were the top two Mutual Funds as of Aug 31, 2024. The former held 17.81 shares worth $19778.0, making up 0.16% of all outstanding shares. On the other hand, Brinker Capital Destinations Tr-Destinations Multi Strategy Alt Fd held roughly 7.03 shares worth around $7813.0, which represents about 0.06% of the total shares outstanding.
